Spots Global Cancer Trial Database for Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Official Title: An Observational Study to Evaluate the Real-world Experience of Patients Who Are Initiating Treatment With Telotristat Ethyl (XERMELO™)
Study ID: NCT03223428
Conditions
Interventions
Study Description
Brief Summary: The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
RTI-HS, Research Triangle Park, North Carolina, United States
Contact Details
Name: Lonnie Brent, PhD
Affiliation: TerSera Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
